Mercaptamine

Phase 3Small molecule

RRECORDATI GROUP

Mercaptamine is one of 9 small molecule programs targeting Cystinosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CystinosisActive, not recruiting

CystinosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Cystinosis

#DrugCompanyPhaseTrials

Acetadote

AArbor Pharmaceuticals, Inc.

N-Acetyl Cyteien

1 3

RP103

Amgen

Phase 3

3 4

Cystagon

Amgen

Phase 2

3 5

Mercaptamine

RRECORDATI GROUP

Phase 3

1 6

ELX-02

EEloxx Pharmaceuticals, Inc.

Phase 2

1 7

Cystadrops

LLeadiant Biosciences, Inc.

Preclinical

3 8

Procysbi

HHorizon Therapeutics Ireland DAC

Preclinical

3 9

N-Acetylcysteine Amide

NNacuity Pharmaceuticals, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystinosis1 trial

Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2)

Completed·RRECORDATI GROUP·Phase 3·NCT04125927·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mercaptamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mercaptamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mercaptamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RECORDATI GROUP company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRECORDATI GROUP

Mercaptamine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cystinosis1 trial

References

Drug Info

Quick Facts

Related News